🇺🇸

US SEC Filing Intelligence

· daily

US SEC Filings Daily Market Digest — March 05, 2026

Across 481 SEC filings for March 5, 2026, US markets show mixed corporate health with retail leaders like Burlington Stores (+9% FY sales, +2% comps) and BJ's (+4.6% FY sales) outperforming amid modest guidance (Burlington FY26 +8-10%), while consumer names like GoPro (-19% revenue) and Grove Collaborative (-15%) struggle with margin erosion. Biotech and pharma exhibit robust revenue surges (REGENXBIO +105% YoY, Lexicon +60%, Cryoport +12.4%) but persistent net losses and cash burn, offset by positive pipeline catalysts (e.g., Tenaya-Alnylam collab up to $1.13B milestones). Energy firms report production gains (Granite Ridge +27% YoY Q4, SandRidge +12% FY) and reserve growth (+9.5-15%), though revenues vary with prices; SPAC activity surges with Pasqal's $2B merger and multiple quantum deals. Portfolio trends reveal margin compression in 8/15 tech filings (avg -120bps despite +15-30% revenue), retail comp sales +1-5% avg in outperformers vs declines elsewhere, and capital returns via buybacks/dividends in 12 firms (e.g., EPAM $300M ASR, Kroger $7.5B repurchase). Insider patterns absent but management conviction via repurchases in Ranger (994k shares), Burlington ($117M Q4). Forward catalysts cluster in Q2 2026 (Northern Data acquisition, Pasqal Nasdaq listing, multiple earnings). Overall, actionable alpha in energy production plays and retail leaders amid quiet M&A uptick.

253 high priority 228 medium 481 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 05, 2026

Across 71 SEC filings from diverse sectors mislabeled under S&P 500 Consumer Discretionary (including energy, financials, tech, and true disc like entertainment), overarching themes include robust revenue/production growth averaging 20-50% YoY in 25+ companies (e.g., Granite Ridge +27% prod, FTC Solar +149% Q4 rev, Profound Medical +50%), tempered by persistent net losses or margin compression in 30+ firms due to higher opex/LOE (e.g., flyExclusive retail -39% Q4, Mobile Infra rev -5%). Capital allocation shines with aggressive buybacks (Zillow +$1.25B to $1.3B capacity, Paycom +$200M) and dividend hikes (Korn Ferry +14.6% to $0.55), signaling management conviction amid mixed sentiment (45/71 mixed/neutral). Forward-looking data reveals optimistic 2026 guidances in energy/tech (SandRidge 6.4-7.7 MMBoe, Bridger $135-145M rev, TriSalus $60-62M), spin-offs (Aptiv Versigent April 1), and divestitures (Six Flags $331M parks sale). Portfolio-level trends show outperformance in production/reserves growth (energy avg +15-28% YoY) vs deteriorating retail/consumer metrics (flyExclusive fractional retail -8% YTD, NIKE $300M restructuring charges). Critical implications: prioritize capital return plays and guided growth; avoid prolonged loss-makers like Research Frontiers (cash -67%).

32 high priority 39 medium 71 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 05, 2026

Across 31 SEC filings from the USA S&P 500 Healthcare stream (with broader S&P exposure), overarching themes include robust revenue growth in healthcare/biotech (e.g., TriSalus 53% YoY to $45.2M, Caribou 12% to $11.2M) and select financials (South Plains 13.6% NII growth), offset by pervasive margin compression (TriSalus GM -150bps to 84.6%, Ciena -20bps to 43.8%) and widening net losses (TriSalus -30.6% to $39.2M, Caribou flat at $148M amid impairments). Mixed sentiment dominates (14/20 detailed), driven by top-line beats/guidance reaffirms (TriSalus exceeded FY25, reaffirms 2026 $60-62M) but elevated costs/op-ex (S&M/G&A up double-digits across biotech) and litigation costs (Moderna $950M settlement). Capital allocation favors buybacks (Ciena $80.5M, News Corp $1B program) and dividends (NewLake Q1 2026 $0.43/share), with healthcare firms pursuing M&A/raises (TriSalus $46M offering, Moderna royalty-free license). Portfolio-level trends show 7/12 revenue reporters >20% YoY growth but 6/8 with op loss expansion; proxy season ramps with 8 Apr 2026 meetings signaling comp votes amid strong TSR (BNY 178%, First Business 235%). Critical developments: litigation resolutions (Moderna) and board enhancements (PacBio AI expert) provide catalysts, implying selective healthcare upside amid financial stability.

17 high priority 14 medium 31 total filings
· daily

Global High-Priority Regulatory Events — March 05, 2026

Across 285 filings from March 5, 2026, key themes include a surge in SPAC IPOs and mergers (e.g., Pasqal at $2B valuation, QuasarEdge, KPET), quantum computing catalysts (Pasqal, Xanadu), and distress in infrastructure/energy (multiple Jaiprakash defaults at ₹55k Cr debt, Cumulus Chapter 11, SKIL insolvency). Period-over-period trends show mixed revenue growth (avg +12% YoY in airlines/tech like LATAM +11%, CrowdStrike +22%; declines in media/energy like StubHub -1.4%, Stabilis -6.9%), margin compression in 15/50 quantified cos (avg -100bps, e.g., Full House EBITDA flat), and capex/debt rises amid M&A. Biotech/pharma mixed (Tenaya-Alnylam collab $1.13B milestones positive; Immatics loss swing), with positive leadership changes (SentinelOne CFO, Delta exec shuffles). Insider conviction low (no buys noted, sales rare), capital returns via buybacks (EPAM $300M ASR, Sysco reaffirmed). Portfolio-level: 40% mixed sentiment, quantum/SPAC bullish outliers, Indian insolvencies drag EM. Actionable: Monitor Q2-Q3 deal closes, CoC meetings.

285 high priority 285 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 05, 2026

The IPO pipeline shows robust activity on March 5, 2026, with two Cayman-based SPAC S-1 filings (QuasarEdge/QRED for $100M and KPET for $200M), a microcap charter fishing IPO (Arvana/AVNI), and Visa's S-4 exchange offer, highlighting a mix of blank-check vehicles and follow-on structures amid mixed/neutral sentiments. Period-over-period trends are sparse but reveal AVNI's FY2024 revenue flat at -0.5% YoY ($67,964 vs $68,276) yet net loss slashed 66% to $447k via 23.1% op ex cuts, contrasting SPACs' pre-revenue status with high dilution (QRED up to $8.19/share). Critical developments include QRED's PRC regulatory risks and Visa's uncapped litigation makewhole agreements, implying caution for public shareholders. Portfolio-level patterns indicate SPAC resurgence with larger average raises ($150M) but elevated redemption/dilution scenarios, while AVNI flags small-cap operational recovery post-hurricanes/repairs. Market implications favor monitoring de-SPAC catalysts over immediate IPO pops given mixed materiality (avg 9.5/10) and no historical performance data.

4 high priority 4 total filings
· daily

US Earnings Financial Results SEC Filings — March 05, 2026

Across 109 US SEC filings for Q4 FY2025/early FY2026 financial results, overarching themes include mixed revenue performance with ~55% of companies (60/109) reporting YoY growth averaging +25% (outliers like Liquidia +1031%, Hippo +26%), offset by declines in ~30% averaging -10% (e.g., Olaplex flat, Rayonier -10%), driven by sector-specific pressures in industrials/energy and boosts in biotech/fintech from collaborations/new products. Profitability improved in 65% with average net loss narrowing ~35% YoY via cost controls/impairment reversals, though 25% swung to losses amid impairments (StubHub $1.91B loss). Margin trends show compression averaging -80bps in tech/manufacturing (7/12 firms, e.g., CPI Card -430bps), expansion +150bps in financials (NIM +25bps avg across 12 banks). Capital allocation favors dividends/buybacks in 18 firms (e.g., Toro repurchases), with debt surges in 20% post-refinancing (Ferrellgas +78%). Biotech/pharma (35 filings) dominate with collab revenue +48% avg but high R&D burns; positive sentiment in 5% (Okta, CorMedix). Portfolio implication: Bullish on profitable growers (TaskUs +123% NI), cautious on high-burn biotechs; alpha in NIM-expanders amid rate cuts.

109 high priority 109 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 05, 2026

Across 12 DEF 14A proxy statements filed around March 5, 2026, a dominant theme is seeking advisory approval on 2025 executive compensation packages, director elections, and auditor ratifications ahead of clustered April 2026 annual meetings, with virtual formats in 11/12 cases. Financial firms like BNY Mellon (178% TSR outperforming S&P Financials 2.5x, 18% annualized EPS growth 2022-2025), First Business Financial (235% 5yr TSR vs peer median 66%, 11% YoY deposit growth), and Publix (superior results with peer-low comp) highlight strong period-over-period performance justifying pay, contrasting neutral filings lacking metrics. Capital allocation shines in PPG Industries ($1.9B op cash flow, $790M buybacks or 3% shares, 54th consecutive dividend hike) amid flat 2% organic sales. Portfolio-level trends show 4/12 with bullish metrics (revenue/EPS/TSR outperformance), mixed in industrials, neutral elsewhere; high prior say-on-pay support (e.g., BNY 95%) signals low dissent risk. Market implications include potential stock boosts post high-vote approvals, governance enhancements via new directors (Publix +1 to 9), and watch for SPAC merger risks in Relativity. Overall, financial sector conviction high, supporting overweight amid 2026 catalysts.

12 high priority 12 total filings
· daily

US Executive Officer Management Changes SEC — March 05, 2026

Across 34 SEC filings on US executive and director changes dated March 5, 2026, a dominant theme is proactive board refreshes and strategic leadership appointments, with 18 positive sentiment filings highlighting expertise in AI, growth, M&A, and operations, signaling confidence in scaling amid competitive markets. CFO/CAO transitions are prevalent (9 cases), including retirements (Cardinal Health, McKesson), departures to peers (Sysco's Cheung to McKesson), and promotions (GEO, Trulieve), with no major operational disruptions noted but smooth handovers emphasized. Where enriched data provides period trends, standout growth includes PACS Group's 2025 revenue +29.3% YoY to $5.29B and Sysco's FY2025 sales >$81B, alongside reaffirmed FY2026 guidance at high-end EPS $4.50-$4.60 despite CFO exit. Neutral sentiment dominates (16 filings) on routine changes, with few bearish signals like terminations without cause (Trulieve CAO) or role eliminations (Match COO). Portfolio-level patterns show healthcare/distribution sectors leading in C-suite stability via internal promotions, while tech/biotech adds AI/defense talent for innovation catalysts. Capital allocation leans toward retention via equity grants/RSUs (e.g., Invitation Homes $11.3M CEO LTIP, SentinelOne $18M CFO equity), with no dividend/buyback shifts but increased incentives tied to EBITDA/TSR. Implications favor long-term holders in refreshing boards, watch CFO handovers for earnings volatility.

34 high priority 34 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — March 05, 2026

In the USA Corporate Distress & Bankruptcy intelligence stream covering 51 filings from March 5, 2026, distress signals are limited with only two active Chapter 11 cases (Cumulus Media prepackaged plan with 72% support, TPI Composites asset sales amid DIP default), overshadowed by 20+ positive financings/refinancings (e.g., Pulmonx $60M term loan, Sunrise Realty $165M rev fac expansion) and debt tenders (Sirius XM $499M repurchased, Matador $420M). Period-over-period trends show mixed revenue performance: growth in OptimizeRx (+19% FY2025 YoY), Full House (+3.4% Q4 2025 YoY), but declines in GoPro (-19% FY2025 YoY) and implied sector weakness (Cumulus declining broadcast). Reverse stock splits in 5 small caps (Reviva 1:20, Aditxt/Sky Quarry 1:8, Salarius 1:12) flag microcap distress, while capital allocation leans bullish with buybacks (EPAM $300M ASR, OptimizeRx $10M program) and divestitures (Six Flags $331M for debt paydown, Community Health $112M). Forward-looking catalysts cluster in Q2 2026 (deal closings, approvals), suggesting deleveraging and liquidity boosts could stabilize portfolios. Portfolio implication: overweight structured distress resolutions and financing winners, underweight reverse-split microcaps amid Nasdaq deficiencies (Fly-E).

51 high priority 51 total filings
· daily

US SEC Trading Suspension Halt Orders — March 05, 2026

Across the single filing in the USA Trading Suspensions stream, Fly-E Group, Inc. (FLYE) faces significant regulatory headwinds with a Nasdaq deficiency notice for untimely 10-Q filing for the period ended December 31, 2025, and an ongoing SEC investigation initiated January 21, 2026. No period-over-period financial trends are detailed in the enriched data, but the late filing signals potential operational or reporting delays QoQ into Q4 2025. Sentiment is uniformly negative with high materiality (9/10), highlighting risks of delisting if compliance is not achieved by April 28, 2026, or extended to August 24, 2026. No immediate impact on trading or listing status provides short-term stability, but the dual regulatory pressures underscore vulnerability for emerging growth companies on Nasdaq. Key implications include heightened short-term volatility and potential suspension if unresolved, with no bullish portfolio-level patterns evident in this isolated case.

1 high priority 1 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — March 05, 2026

Cumulus Media Inc., the sole filing in this Bankruptcy & Insolvency intelligence stream, announced a prepackaged Chapter 11 plan of reorganization, highlighting severe liquidity pressures and a declining broadcast radio industry with no quantified operational improvements. Key creditors holding 72.05% of 2029 Secured Debt Claims have committed support via a Restructuring Support Agreement, signaling likely plan confirmation but underscoring deep financial distress. The debtors' board strongly recommends acceptance by the April 7, 2026 voting deadline, yet equity holders face probable wipeout or severe dilution in this negative sentiment (10/10 materiality) scenario. No period-over-period financial trends, insider trading, or capital allocation details were quantified, but ongoing industry decline points to structural headwinds. Market implications include heightened volatility for CUMULUS MEDIA INC (CMLS) equity, potential short opportunities, and distressed debt plays ahead of case commencement.

1 high priority 1 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 05, 2026

Across 34 US SEC filings dated March 5, 2026, focused on board room changes, a dominant theme is proactive board refreshments and C-suite transitions, with 18 positive sentiment announcements (e.g., expert director additions at AZZ, Janus, PacBio) signaling strategic enhancement amid growth strategies. Neutral sentiments prevail in 13 cases involving retirements/planned successions (e.g., Cardinal Health CAO retire Feb 2027, McKesson CFO May 2026), minimizing disruption, while 2 negative/mixed cases highlight risks (Match Group COO elimination, Sysco CFO to Fortune 10). Sparse but positive period trends include PACS revenue +29.3% YoY to $5.29B, Sysco FY25 sales >$81B with FY26 EPS guidance reaffirmed at high-end $4.50-$4.60, and WEBTOON 160M MAUs. Forward-looking catalysts cluster in Q2 2026 (multiple effective dates), with comp plans tying awards to EBITDA/ROIC/TSR (e.g., Invitation Homes NOI CAGR targets to 2028). Portfolio-level: High talent mobility (e.g., Kenny Cheung Sysco to McKesson), board independence rising (AZZ 7/8 independent), implying sector confidence but CFO/CAO churn (9 instances) warrants monitoring for execution risks. Actionable: Favor healthcare/tech with deep benches (Delta, SentinelOne), avoid abrupt terminations (Trulieve, Match).

34 high priority 34 total filings
· daily

US Merger & Acquisition SEC Filings — March 05, 2026

The USA M&A & Takeover Activity stream reveals a surge in SPAC activity with 8 out of 12 filings tied to blank check companies, including IPOs raising over $1.1B collectively (Averin $284M, Fortress $250M, TRG $200M, Kensington $200M, GalaxyEdge $100M), extensions (Athena), and unit separations (OneIM), signaling robust dealflow targeting tech, AI, quantum, LatAm, automotive/defense/energy. Actual M&A highlights include Pasqal's $2B SPAC merger with Bleichroeder offering $600M proceeds amid 100% 2025 revenue growth, and T Stamp's acquisition of Lexverify for LLM expertise. Camp4 Therapeutics reported mixed FY2025 results with revenue exploding 437% YoY to $3.5M and cash runway to 2028, but net loss widened 55% YoY to $80.4M due to non-cash charges. Period-over-period trends show strong fundraising momentum but pockets of financial strain like Fortress's $13.2M shareholders' deficit post-IPO and Invest's material weaknesses in controls. Portfolio-level patterns indicate heightened M&A appetite in quantum computing, biotech, and AI, with H2 2026 catalysts from closings and trials; implications favor long SPAC proxies and targets ahead of redemptions.

12 high priority 12 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 05, 2026

Across 128 overnight SEC filings, retail and consumer sectors showed resilient top-line growth (e.g., Burlington +11% YoY sales, BJ's +5.5% Q4) but frequent margin compression (avg -100bps in 6/10 retailers) amid tariffs and costs, while biotech/pharma exhibited mixed results with strong product ramps (Liquidia +1031% revenue) offset by R&D spikes and losses. Quantum computing SPACs like Bleichroeder/Pasqal ($2B valuation, $600M proceeds) and Xanadu signal hot M&A in emerging tech, contrasting energy services' pricing pressures (Ranger Wireline -45% YoY). Capital allocation leaned shareholder-friendly with $10B+ in buybacks/dividends (Kroger $7.5B+$2B, EPAM $300M ASR, Ranger FCF >40% to repurchases/dividends). Guidance trends modest for 2026 (e.g., Burlington comps 1-3%, Kroger identical sales 1-2%) but positive outliers like Ciena raised FY26 to $5.9-6.3B (+28%). Portfolio-level: 45/128 positive sentiment, 60 mixed, 10 negative; YoY revenue growth avg +15% in winners but -20% in laggards like Silence (-99%). Key implication: Favor growth retail/biotech turnarounds with strong FCF, monitor quantum M&A redemptions.

65 high priority 63 medium 128 total filings
· daily

Biotech Small-Cap Approvals — March 04, 2026

Biotech small-cap approvals in this period featured 5 neutral generic ANDA/NDA entries, signaling routine portfolio expansion for sponsors like Apotex, Almatica, Macleods, Humanwell, and Anthea amid pricing and competition risks. The sole high-impact event was Ascendis Pharma's NAVEPEGRITIDE approval (NME, Priority Review, Orphan), a bullish catalyst with premium pricing potential despite unspecified indication. Overall, 83% neutral signals highlight limited innovation, constraining sector-wide conviction without market size details.

6 total filings
· daily

Big Pharma Approvals — March 04, 2026

This period yields four neutral signals from Big Pharma approvals, with only Janssen's PREZCOBIX (darunavir/cobicistat) providing substantive details on a standard-review original NDA approved 2026-02-27. Three identical, empty records for Novo Nordisk's SOMAPACITAN-BECO represent 75% concentration but offer zero insights, signaling potential data gaps. No bullish/bearish catalysts emerge; monitor for label clarity to assess portfolio impact.

4 total filings
· daily

Orphan Drug Approvals — March 04, 2026

Two Priority Review orphan drug approvals on 2026-02-27 deliver bullish catalysts for Ascendis Pharma and BioMarin Pharm, with NME status for Ascendis' NAVEPEGRITIDE and efficacy supplement for BioMarin's PEGVALIASE-PQPZ. Orphan designations across both enable 7-year market exclusivity and premium pricing in rare disease markets. Unspecified indications cap addressable market visibility, warranting caution on revenue potential.

2 total filings
· daily

New Drug Approvals (Original) — March 04, 2026

This one-day snapshot reveals 7 FDA approvals dominated by 4 routine ANDA generics (Apotex, Macleods, Humanwell, Anthea) with neutral implications due to pricing pressures and unspecified markets. A single high-impact bullish signal emerges from Ascendis Pharma's NME-priority-orphan approval for NAVEPEGRITIDE (YUVIWEL), signaling premium pricing potential and biotech upside. Overall neutral period for institutional portfolios, with limited sector visibility absent therapeutic details.

7 total filings